The Tisch Cancer Institute | Strategic Alliance Partners

May 26, 2022

Mount Sinai researcher Natasha Kyprianou, MBBS, PhD, a leading expert on prostate, bladder, and kidney cancer, has been awarded the Richard D. Williams, MD, Prostate Cancer Research Excellence Award by the Urology Care Foundation, the world’s leading nonprofit urological health foundation and official foundation of the American Urological Association.

May 24, 2022

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.

May 18, 2022

Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic.

May 15, 2022

Matthew Galsky, MD, discusses long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer.

May 14, 2022

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

May 09, 2022

Mount Sinai researchers have developed a novel method to identify aggressive early-stage lung cancers and target drugs known as aurora kinase inhibitors to tumors that are especially likely to respond to them.

May 04, 2022

Most immunocompromised people with multiple myeloma benefited from a third dose of COVID-19 vaccines. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge

May 03, 2022

Mount Sinai researchers conducting clinical trials of a drug targeting a cancer gene found that it increased metastatic cancer patients’ survival and was able to work within the brain.

April 22, 2022

Matthew Galsky, MD, discusses the impact of recent developments in the advanced urothelial carcinoma treatment paradigm.

April 07, 2022

Researchers at the Icahn School of Medicine at Mount Sinai describe a troubling increase in early-onset colorectal cancer and precancerous polyps, based on a large, nationally representative study of patients under age 50 who underwent colonoscopy.

April 03, 2022

Results from first-of-its-kind Mount Sinai study show that immunotherapy before liver cancer surgery can kill tumor, and likely residual cancer cells.

March 30, 2022

Next-generation spatial genomics technology paves the way for accelerating the discovery of new cancer drug targets

March 14, 2022

Ketan K. Badani, MD, discusses the evolution of robotic retroperitoneal partial nephrectomies in renal cell carcinoma.

March 07, 2022

Sundar Jagannath, MBBS, discusses the significance of the FDA approval of ciltacabtagene autoleucel, important adverse effects to be aware of, and shared his thoughts on where the treatment fits into the current and future treatment paradigms.

March 03, 2022

Sundar Jagannath, MBBS, discusses the FDA approval of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

March 02, 2022

Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.

February 16, 2022

Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy​ for a patient with prostate cancer.

February 09, 2022

The Tisch Cancer Institute at Mount Sinai and the Samuel Waxman Cancer Research Foundation are launching a unique research program that will fund collaborations between TCI physician-scientists and colleagues from other established cancer research institutions to address the rising rates of cancer due to aging around the world.

January 24, 2022

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer.

January 24, 2022

Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.